RankingsPricing
  1. US-listed companies
  2. ABEONA THERAPEUTICS INC.
  3. Raw

ABEONA THERAPEUTICS INC.ABEO

Market cap
$248.11M
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net loss-2,532,000-10,532,0004-26,778,000-14,526,000-21,873,000-27,319,000-56,671,000-76,282,000-84,234,000-84,936,000-40-54-64
Depreciation and amortization233,000419,0003,00011,000551,000825,000741,0002853322
Stock-based compensation expense1390,000439,00014-------57
Change in fair value of warrant and derivative liabilities------------11121
Accretion and interest on short-term investments-----------00-0
Amortization of right-of-use lease assets----------1111
Non-cash interest-------------2
(Gain) loss on disposal of property and equipment------------0-47,0002,000
Other receivables-----------02-1
Prepaid expenses and other current assets-31,000212,000-174,000-77,000287,000-160,00031-670,000-424,000-331,000-201
Other assets15,000-17,000-10,000-29,0004,000---3,000127,0007,000-00-0
Accounts payable and accrued expenses53,000567,000-1,176,00033,000-1,174,000-------522
Lease liabilities-------------1-1
Change in payable to licensor------------5--5
Other current liabilities-------------00
Net cash used in operating activities-7,609,000-3,955,0001,000----22,935,000-39,111,000-62,820,000-35,019,000-66-43-37-56
Capital expenditures40,00013,0002,000-308,000519,000860,0009614002
Proceeds from disposal of property and equipment----4------200
Purchases of short-term investments---------170207852157
Proceeds from maturities of short-term investments--------6688905352120
Net cash (used in) provided by investing activities-40,000-13,000-2,000----860,000-85,086,00060-83,714,00066-240-39
Proceeds from ATM sales of common stock, net of issuance costs6--127---17-8131415
Proceeds from sales of common stock under direct placement offering, net of issuance costs------------23-
Payments related to net settlement of restricted share awards-------------0-1
Proceeds from sales of common stock, net of issuance costs-------------70
Proceeds from issuance of long-term debt-------------20
Payment of debt issuance costs------------01
Net cash provided by financing activities3229,000---9251142254337104
Net increase in cash, cash equivalents and restricted cash--------118,720,000111-116,797,00025-2409
Derivative and warrant additions associated with loan and security agreement-------------1
Reclassification of derivative liability to equity-------------1
Changes in accrued property and equipment-------------0
Cash paid for interest------8,00011,000-----3
Cash paid for taxes-------------0